{"article":{"annotation":{"article_id":"brazil-anvisa-bans-irregular-medicines-october-2026","available_at":"2026-10-06T23:11:48.041355Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"9b4ec96012aa0c05605eea6f054fda9f375efca6fcac5c933ef48d5f1453c661","input_sha256":"45da2698cdfa8ef808029fa48b777229256690afeaa975a53200bd994e60f02e","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"BR","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"geometry":null,"id":"iso3166-1:BR","kind":"country-or-area","labels":{"ar":"البرازيل","en":"Brazil","es":"Brasil","fr":"Brésil"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"d28c9c89703b56bd91fd887965d416d0115c2473d4bfbd3e558bcceafc3941dd","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=de","category":"health","content":{"key_points":[],"paragraphs":["Die brasilianische Gesundheitsaufsicht Anvisa verbot am 6. Oktober den Verkauf mehrerer nicht konformer Arzneimittel. Die Maßnahmen betreffen Insulin glargin, das von einem nicht zugelassenen Unternehmen vertrieben wurde, ein zusammengesetztes Arzneimittel, das ohne Verschreibungen öffentlich vermarktet wurde, sowie nicht registrierte Peptide.","Anvisa meldete außerdem den freiwilligen Rückruf einer Charge Imaavy durch den Hersteller und ordnete den Rückruf einer Charge des Antibiotikums Lizbi an, nachdem ein mit beschädigter Verpackung verbundener Verlust der Sterilität bestätigt worden war. Dieser Bericht beschreibt behördliche Maßnahmen und ist keine individuelle Behandlungsempfehlung."],"sections":[]},"corrections":[{"at":"2026-10-07T00:55:00+03:00","language":"de","text":"Dieser Artikel wurde um eine deutsche und eine portugiesische Ausgabe sowie entsprechende Übersetzungen der Daten- und Korrekturhinweise ergänzt."}],"country":"BR","data":{"blocks":[{"columns":[{"key":"item","label":{"ar":"المنتج أو الفئة","de":"Produkt oder Kategorie","en":"Product or category","es":"Producto o categoría","fr":"Produit ou catégorie","pt":"Produto ou categoria","tr":"Ürün veya kategori"},"language":"en","type":"text"},{"key":"action","label":{"ar":"إجراء أنفيسا","de":"Maßnahme von Anvisa","en":"Anvisa action","es":"Medida de Anvisa","fr":"Mesure de l’Anvisa","pt":"Medida da Anvisa","tr":"Anvisa işlemi"},"language":"en","type":"text"}],"description":{"ar":"فئات المنتجات وأنواع الإجراءات في إعلان أنفيسا بتاريخ 6 أكتوبر 2026.","de":"Produkte und Maßnahmen in der Mitteilung von Anvisa vom 6. Oktober 2026.","en":"Products and action types in Anvisa’s October 6, 2026 notice.","es":"Productos y tipos de medidas del aviso de Anvisa del 6 de octubre de 2026.","fr":"Produits et types de mesures dans l’avis de l’Anvisa du 6 octobre 2026.","pt":"Produtos e tipos de medida no comunicado da Anvisa de 6 de outubro de 2026.","tr":"Anvisa’nın 6 Ekim 2026 duyurusundaki ürün grupları ve karar türleri."},"id":"brazil-anvisa-regulatory-actions","methodology":{"ar":"يلخص الجدول نطاق الإعلان وفق نص المصدر؛ ولا يقدم إرشاداً طبياً.","de":"Die Tabelle fasst den Umfang der Mitteilung mit den Begriffen der Quelle zusammen und enthält keine medizinische Beratung.","en":"The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance.","es":"La tabla resume el alcance del aviso según el texto fuente; no ofrece orientación médica.","fr":"Le tableau résume le champ de l’avis selon le texte source ; il ne fournit pas de conseil médical.","pt":"A tabela resume o escopo do comunicado nos termos da fonte; não fornece orientação médica.","tr":"Tablo karar kapsamını kaynak metindeki ifadelerle özetler; listelenen ilaçlar için tıbbi öneri içermez."},"rows":[{"action":"Sale of all lots prohibited; distributor lacked authorization.","item":"Insulin glargine 3 mL/100 IU, Costa Mar"},{"action":"Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.","item":"Vermefree compounded medicine, Sintonia Pharma"},{"action":"Sale, manufacture, distribution, advertising, transport and use prohibited.","item":"Unregistered peptides listed in notice"},{"action":"Voluntary recall reported; possible glass particles in vials.","item":"Imaavy batch JNYJ1201"},{"action":"Recall ordered after confirmed sterility loss linked to compromised primary packaging.","item":"Lizbi batch 0000207107"}],"sourceUrls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"],"title":{"ar":"الأدوية المحظورة أو المسحوبة","de":"Verbotene oder zurückgerufene Arzneimittel","en":"Medicines prohibited or recalled","es":"Medicamentos prohibidos o retirados","fr":"Médicaments interdits ou rappelés","pt":"Medicamentos proibidos ou recolhidos","tr":"Yasaklanan veya geri çağrılan ilaçlar"},"type":"table","updatedAt":"2026-10-07T00:55:00+03:00"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=de&format=csv","json":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=de&format=json"},"id":"brazil-anvisa-regulatory-actions"}],"data_types":["table"],"editorial_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-8ff1924c-3faa-55d0-982f-f85ffe24522b","event_period":"2026-10-06","event_period_basis":"event-or-reference-period","id":"brazil-anvisa-bans-irregular-medicines-october-2026","image":null,"importance":0.6,"language":"de","modified_at":"2026-10-07T00:55:00+03:00","publication_basis":"publication-record","published_at":"2026-10-06T17:11:49+00:00","reading_minutes":1,"region":"world","section_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"brazil-anvisa-bans-irregular-medicines-october-2026","sources":[{"checkedAt":"2026-10-06","name":"National Health Surveillance Agency of Brazil","publishedAt":"2026-10-06","url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"}],"summary":"Die Verbote betreffen nicht genehmigt vertriebenes Insulin, ein unsachgemäß hergestelltes Präparat und nicht registrierte Peptide sowie zwei Arzneimittelchargen mit Qualitätsproblemen.","text":"Die Verbote betreffen nicht genehmigt vertriebenes Insulin, ein unsachgemäß hergestelltes Präparat und nicht registrierte Peptide sowie zwei Arzneimittelchargen mit Qualitätsproblemen.\n\nDie brasilianische Gesundheitsaufsicht Anvisa verbot am 6. Oktober den Verkauf mehrerer nicht konformer Arzneimittel. Die Maßnahmen betreffen Insulin glargin, das von einem nicht zugelassenen Unternehmen vertrieben wurde, ein zusammengesetztes Arzneimittel, das ohne Verschreibungen öffentlich vermarktet wurde, sowie nicht registrierte Peptide.\n\nAnvisa meldete außerdem den freiwilligen Rückruf einer Charge Imaavy durch den Hersteller und ordnete den Rückruf einer Charge des Antibiotikums Lizbi an, nachdem ein mit beschädigter Verpackung verbundener Verlust der Sterilität bestätigt worden war. Dieser Bericht beschreibt behördliche Maßnahmen und ist keine individuelle Behandlungsempfehlung.\n\nDieser Artikel wurde um eine deutsche und eine portugiesische Ausgabe sowie entsprechende Übersetzungen der Daten- und Korrekturhinweise ergänzt.","title":"Anvisa verbietet den Verkauf nicht konformer Arzneimittel in Brasilien","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/brazil-anvisa-bans-irregular-medicines-october-2026"}],"url":"https://newsverum.com/de/news/brazil-anvisa-bans-irregular-medicines-october-2026"},"version":"1"}